Suven Life Sciences Ltd's earnings have declined by -175.9%, whereas share price has declined -9.6% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.
Suven Life Sciences Ltd share price has appreciated 21.5% annually (CAGR) over the past ten years.
Past 10 years financial track record analysis and assessment of future prospects by Moneyworks4me indicates that Suven Life Sciences Ltd is an average long term investment. However, you need to ensure you buy at a right price to earn good returns.
Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
Shares are listed at Bombay Stock Exchange (BSE), National Stock Exchange (NSE), and Hyderabad Stock Exchange(HSE). It has a state of the art R&D center recognized by Department of Scientific & Industrial Research (DSIR), Ministry of Science and Technology, Government of India. Also, it has world class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Life Science Companies for New Chemical Entities (NCE's).
The companyâ€™s main thrust is in Contract Research and Manufacturing Services (C-R-A-M-S). Suven's â€˜C-R-A-M-Sâ€™ is in existence since 1991 serving as many as 22 global Life Science and Fine Chemical Companies by developing and supplying cost effective Pharmaceutical and Agro Chemical Intermediates for New Chemical Entities (NCE's) meeting world standards of Quality, Speed and Respect for Environment.
Drug Discovery & Development Support Services (DDDSS) aims to provide Contract Drug Discovery & Development services in Medicinal chemistry, Process chemistry, Analytical chemistry, In-vitroScreening, DMPK, Brain Microdialysis, CV Safety, In-vivo Metabolic Disorders & CNS Pharmacology, Phase-I Bio-analysis and Discovery Toxicology.
Suven Nishtaa Pharma
Suven Nishtaa Pharma (Suven Nishtaa), a joint venture company of Suven Life Sciences, is a Pharmaceutical Formulations Contract Services provider.
Suven Nishtaa, a 100% Export Oriented Unit, is engaged in providing end-to-end Drug Product Development services, viz.